ALLURION TECHNOLOGIES INC SEC Filings

Allurion Technologies (ALUR) amended its quarterly report to reflect a prior restatement and to disclose post-business-combination corporate and financing activity. The company completed a business combination with Compute Health and applied a reverse stock split, which changed warrant and share conversion ratios. It disclosed multiple equity and warrant offerings closed in January and February 2025 that raised net proceeds of $5.8 million and $3.9 million, respectively, and additional private placements raising $2.5 million and $1.3 million. The company described amendments to a revenue interest financing agreement that increased revenue-interest rates and related derivative accounting, conversions and debt modifications, and recorded related liabilities and remeasurements. Allurion operates in ~50 countries, provides the Allurion Program and App for remote patient monitoring, and disclosed remediation steps for previously identified internal control weaknesses and an NYSE cure plan.

Allurion Technologies (ALUR) amended its annual report describing strategic, operational and financial risks tied to its post‑merger transition and commercialization of the Allurion Balloon. The company completed a Business Combination with Compute Health and various financings including a July 1, 2024 public offering that raised net proceeds of $15.2 million and multiple private placements. Allurion sells the Allurion Balloon and an AI‑powered Virtual Care Suite (VCS) in over 40 countries but the Balloon is not approved for commercial sale in the U.S. The filing discloses a restatement of prior financial statements, material weaknesses in internal controls, significant debt and revenue‑interest financing with RTW that carries contingent payment rates and covenants. The company states it has incurred losses and expects losses to continue while FDA approval, regulatory compliance, NYSE cure planning, supply, and reimbursement risks remain material.

Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time. The notice identifies Brendan M. Gibbons, Chief Legal Officer as the contact and confirms that other periodic reports required over the prior 12 months have been filed. The company indicates it anticipates a significant change in results of operations for the period and includes customary forward-looking risk disclosures about potential adjustments to prior statements, regulatory or legal actions, possible delisting, and timing uncertainties related to completing and filing the 10-Q.

Allurion Technologies, Inc. disclosed accounting issues requiring correction and potential amendments to prior SEC reports, noting the company does not expect the corrections to affect reported revenue, gross margin, operating expenses, or cash. The filing flags risks including additional adjustments to prior statements, a delayed Q2 Quarterly Report for the period ended June 30, 2025, possible SEC or regulatory investigations, potential NYSE delisting, and shareholder litigation. The statement frames these as forward-looking risks while the company completes its evaluation.

Allurion Technologies said it issued a press release covering results for the three and six months ended June 30, 2025 and disclosed a potential accounting error. The company identified a likely miscalculation in non-cash items—Other Comprehensive Income (Loss) and Other Income (Expense)—related to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes, and believes correcting those calculations will likely require restating prior-period financial statements. The company stated these adjustments are non-cash and are not expected to affect revenue, gross margin, operating expenses, or cash. The press release is furnished as Exhibit 99.1.